Understanding how certain proteins affect treatment response in a type of lung cancer
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma
This study is looking at certain proteins in tumors from patients with malignant pleural mesothelioma to see if they can help doctors figure out who will benefit from new immune treatments, making it easier to choose the right options and improve survival rates.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11094910 on NIH RePORTER |
What this research studies
This research investigates how specific proteins in malignant pleural mesothelioma (MPM) tumors can predict patient responses to immune checkpoint inhibitors (ICIs), a new class of cancer treatments. By analyzing tumor samples using advanced techniques like mass cytometry, the study aims to identify biomarkers that can indicate which patients are likely to benefit from ICIs. This could help avoid unnecessary side effects for those who may not respond and guide treatment decisions for better outcomes. The ultimate goal is to improve survival rates for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with malignant pleural mesothelioma who are considering treatment with immune checkpoint inhibitors.
Not a fit: Patients with other types of cancer or those who do not have malignant pleural mesothelioma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment plans that enhance survival and reduce side effects for patients with malignant pleural mesothelioma.
How similar studies have performed: Other research has shown promising results in using biomarkers to predict responses to immune therapies in various cancers, indicating that this approach has potential.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Burt, Bryan Michael — University of California Los Angeles
- Study coordinator: Burt, Bryan Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.